Clinical Trial Update: Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating lurbinectedin in combination with berzosertib (an ATR kinase inhibitor) for small cell cancers and high-grade neuroendocrine neopla…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• High-grade Neuroendocrine Neoplasm
• Small Cell Carcinoma
• Small Cell Lung Cancer
• Solid Tumor

Drugs mentioned

• Berzosertib (berzosertib)
• Lurbinectedin (lurbinectedin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: SCLC, Small Cell Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING